Mark B. Geyer

IgH class switching and translocations use a robust non-classical end-joining pathway

Catherine T. Yan, Cristian Boboilă, Ellen Kris Souza et al. · Nature · 2007 · 575 citations

Life Sciences, Genetics, Molecular Biology +10

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen et al. · Blood · 2021 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

Monica Bhatia, Zhezhen Jin, Claire E. Baker et al. · Bone Marrow Transplantation · 2014 · 107 citations

Medicine, Hematology, Immunology +12

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

Mark B. Geyer, Isabelle Rivière, Brigitte Sénéchal et al. · JCI Insight · 2019 · 99 citations · Full text

Life Sciences, Immunology, Oncology +16